• Tweet

Biovista announced recently that it has entered into a research collaboration agreement with Novartis. The collaboration is focused on identifying new indications for a number of undisclosed Novartis compounds using Biovista’s Clinical Outcome Search Space (COSS) technology. The terms of the agreement include an upfront payment and success-based milestones.

“We look forward to working with Novartis to enhance their drug discovery efforts” said Aris Persidis, President of Biovista. “Our unique COSS technology offers significant advantages in terms of speed, comprehensiveness and depth of clinical outcome exploration, which we expect will help patients in need of novel solutions,” he added.

The ability to identify novel therapeutic uses for currently available medications is a pragmatic and highly valuable framework to find new medical treatments, particularly since many of the drug efficacy and safety profiling has already been preformed. To this end, Biovista has developed a sophisticated drug repurposing platform that utilizes proprietary drug predictive technology, which not only delineates drug efficacy but also adverse drug effects during drug repurposing. The company’s proprietary discovery platform, termed Clinical Outcome Search Space, enables Biovista to de-risk drug candidates through patient cohort stratification and other methods, reducing the risk of failure as the drugs enter and proceed through the clinic. This unique ability to simultaneously find efficacy and adverse events enables Biovista & its collaborators to win on both sides of drug developments Benefit/Risk equation. The company currently has drug programs for neurological disorders, including multiple sclerosis and epilepsy, as well as for cancer, including glioblastoma and melanoma.

Biovista will be presenting their technology at OneMedForum NY 2011.